TWST CEO executed 476-share tax-withholding sale; retains 632,560 shares
Rhea-AI Filing Summary
Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corporation (TWST), reported a small non-discretionary sale of shares to cover tax withholding related to vested restricted stock units. The filing shows a sale of $29.161 per share for 476 shares on 10/02/2025, described as a mandatory "sell to cover" to satisfy tax withholding; these sales were not discretionary trades by the reporting person. After the transaction, the reporting person beneficially owned 632,560 shares of common stock.
The Form 4 also lists outstanding employee stock options and performance options with various exercise prices and vesting/exercise dates, including options exercisable immediately and a granted performance option that vested on 12/19/2022. The report was signed by an attorney-in-fact on 10/06/2025.
Positive
- Insider sale was non-discretionary and conducted to cover tax withholding, reducing signaling risk
- Substantial remaining ownership with 632,560 shares retained by the CEO, indicating continued alignment with shareholders
Negative
- Outstanding options exist with exercise prices as low as $5.95, representing potential future dilution
- Some options are immediately exercisable, which could lead to stock issuance if exercised
Insights
TL;DR: A routine, mandated "sell to cover" by the CEO reduced holdings by a small number of shares; ownership remains material.
The reported 476-share sale at $29.161 is explicitly described as a mandatory tax-withholding sale tied to vested restricted stock units, which governance best practices treat as non-discretionary and not indicative of a change in insider sentiment. The CEO still holds 632,560 shares, reflecting continued significant ownership.
Dependence on equity compensation remains a governance point to monitor because outstanding options with varying exercise prices and vesting schedules can cause future stock issuance or insider exercise activity; watch near-term vesting/expiration windows around 09/28/2025 through the listed expirations for any additional activity.
TL;DR: Multiple option grants and a vested performance option remain in place; most exercises are non-immediate or already exercised as disclosed.
The filing lists several employee stock options with exercise prices from $5.95 to $67.85 and shows 64,950 shares from a performance option exercisable following vesting on 12/19/2022. Two options are described as immediately exercisable and others vest on standard schedules, indicating ongoing equity dilution potential tied to future exercises.
Key items to watch are the counts and exercise prices of options that are currently exercisable versus those that are not; near-term dilution risk is limited given the small mandatory sale, but option exercises at lower strike prices could be dilutive if executed.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 476 | $29.161 | $14K |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
Footnotes (1)
- Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
